Literature DB >> 21613987

A role for interleukin-33 in T(H)2-polarized intestinal inflammation?

J B Seidelin1, G Rogler, O H Nielsen.   

Abstract

Interleukin 33 (IL-33) is a recently discovered cytokine member of the IL-1 superfamily that is widely expressed in fixed tissue cells, including endothelial and epithelial cells. IL-33 induces helper T cells, mast cells, eosinophils, and basophils to produce type-2 cytokines through binding to the ST2/IL-1 receptor accessory protein complex. Recent studies have shown IL-33 to be upregulated in intestinal parasite infection and in epithelial cells and myofibroblasts in ulcerative colitis (UC). The findings point to a role for IL-33 in directing the T(H)2-type immune responses in these types of mucosal inflammation. As the IL-33/ST2 receptor axis can be manipulated by various blocking antibodies, this could be a potential therapeutic target in the future treatment of UC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613987     DOI: 10.1038/mi.2011.22

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  20 in total

1.  Murine mast cells secrete and respond to interleukin-33.

Authors:  Hui-Ying Tung; Beverly Plunkett; Shau-Ku Huang; Yufeng Zhou
Journal:  J Interferon Cytokine Res       Date:  2013-09-12       Impact factor: 2.607

Review 2.  Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy?

Authors:  Mairi H McLean; Markus F Neurath; Scott K Durum
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

3.  IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis.

Authors:  Jakob Benedict Seidelin; Mehmet Coskun; Peter Helding Kvist; Thomas Lindebo Holm; Kristine Holgersen; Ole Haagen Nielsen
Journal:  J Gastroenterol       Date:  2014-08-12       Impact factor: 7.527

4.  Antibody-mediated trapping of helminth larvae requires CD11b and Fcγ receptor I.

Authors:  Julia Esser-von Bieren; Beatrice Volpe; Manuel Kulagin; Duncan B Sutherland; Romain Guiet; Arne Seitz; Benjamin J Marsland; J Sjef Verbeek; Nicola L Harris
Journal:  J Immunol       Date:  2014-12-29       Impact factor: 5.422

5.  Interleukin-33 exacerbates acute colitis via interleukin-4 in mice.

Authors:  Peter N Pushparaj; Dong Li; Mousa Komai-Koma; Rodrigo Guabiraba; James Alexander; Charles McSharry; Damo Xu
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

6.  Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitis.

Authors:  T Watanabe; Y Sadakane; N Yagama; T Sakurai; H Ezoe; M Kudo; T Chiba; W Strober
Journal:  Mucosal Immunol       Date:  2016-01-27       Impact factor: 7.313

Review 7.  Nematode modulation of inflammatory bowel disease.

Authors:  Rose A K Whelan; Susanne Hartmann; Sebastian Rausch
Journal:  Protoplasma       Date:  2011-11-17       Impact factor: 3.356

Review 8.  Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases.

Authors:  Dulshara Sachini Amarasekara; Jiyeon Yu; Jaerang Rho
Journal:  J Immunol Res       Date:  2015-05-04       Impact factor: 4.818

9.  The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani.

Authors:  Octavie Rostan; Jean-Pierre Gangneux; Claire Piquet-Pellorce; Christelle Manuel; Andrew N J McKenzie; Claude Guiguen; Michel Samson; Florence Robert-Gangneux
Journal:  mBio       Date:  2013-09-17       Impact factor: 7.867

10.  Changes in serum Interleukin-33 concentration before and after treatment with pegylated interferon alfa-2a plus ribavirin in patients with chronic hepatitis C genotype 1b infection.

Authors:  Bruno Cacopardo; Marilia Rita Pinzone; Filippo Palermo; Giuseppe Nunnari
Journal:  Hepat Mon       Date:  2012-12-23       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.